secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001493152-25-017072
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 restores MASPIN and RASSF1A tumor suppressors in prostate cancer models
--------------------------------------------------------------------------------

- Telomir-1 reversed DNA hypermethylation to reactivate MASPIN and RASSF1A in aggressive prostate cancer models.
- MASPIN is a natural defense protein blocking invasion and promoting chemotherapy sensitivity; RASSF1A regulates cell cycle and metastasis suppression.
- Dose-dependent reduction in RASSF1A methylation; stronger effect when combined with chemotherapy.
- Company continues IND-enabling studies for Telomir-1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225017072/0001493152-25-017072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225017072/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-017072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer